TacticScaleWhat Waters Does & How It Makes Money (WAT)
Updated October 2026 · reflects Waters's latest reported financials
Maker of lab instruments for chemical analysis and testing. Waters earns money by selling analytical instruments and software.
How Waters makes money
Waters earns money by selling analytical instruments and software. It also earns ongoing revenue from servicing those instruments and from consumables such as chromatography columns that labs buy again and again.
What Waters does
Waters Corporation, founded in 1958 and based in Milford, Massachusetts, makes analytical workflow tools for laboratories in Asia, the Americas and Europe. It has two segments. The Waters segment designs, makes, sells and services liquid chromatography and mass spectrometry systems, along with chromatography columns and other consumables. The TA segment makes thermal analysis, rheometry and calorimetry instruments, which help predict whether materials such as chemicals, pharmaceuticals, polymers, metals and viscous liquids are suitable and stable for their intended uses. The company also develops software that works with its own instruments and with instruments from other makers. Its mass spectrometry technology is used in drug discovery and development, including clinical trial testing and protein analysis, as well as in food safety and environmental testing. Its customers are pharmaceutical, clinical, biochemical, industrial, academic and government labs working in research and development and quality assurance. Revenue comes from instrument sales and from recurring service and consumables.
Products & services
- Liquid chromatography systems
- Mass spectrometry systems
- Chromatography columns and consumables
- TA thermal analysis, rheometry and calorimetry instruments
- Instrument software
- Instrument service and support
What is Waters worth?
On an owner-earnings DCF, Waters's most-likely value is about $63 versus a recent price near $434 (85% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$34) with a margin of safety — so the honest verdict here is “Stretched — richly priced.” Fair value earns its keep only at the extremes, not in the wide middle.
Today's $434 is above even the optimistic Bull case ($103) — the market expects faster, longer growth than modeled here. Expensive unless that extra growth actually shows up.
⚠ High leverage — net debt is 11.2× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Thermo Fisher Scientific (TMO) · Danaher (DHR) · Agilent Technologies (A) · Solventum (SOLV) · Bruker (BRKR)